

ASX Announcement Spinal Cage FDA Submission Timeline Update

SYDNEY 28th September 2023– Allegra Orthopaedics Limited (**Allegra**) (ASX: AMT) advises, further to the Spinal Cage FDA Submission Update, dated August 4th 2023, regarding the additional information requested by the United States Food and Drug Administration (**FDA**) under the 510(k) pathway in respect to the Sr–HT–Gahnite Spinal Cage Device (**Spinal Cage**) submission, Allegra expects to send the informal response to the FDA within the next 2-3 months. The Company expects to receive feedback thereafter and will incorporate any relevant documents into the final submission which is due 4th February 2024.

Allegra will continue to update the market on any further developments of the Spinal Cage FDA submission.

This announcement has been authorised for release by the CEO of Allegra.

Contact details:

Robyn Slaughter Company Secretary T: +61 2 8072 1435

ABOUT ALLEGRA ORTHOPAEDICS:

We aim to help bring the freedom and happiness of pain-free movement to people's lives. We achieve this through providing the best possible solutions for patients, from world-wide industry leading orthopaedic products through to Australian innovations. Allegra's principal product, the Active Total Knee, has significantly improved the quality of life for many people and remains a focused product line. Allegra is also the exclusive distributor of Waldemar Link GmbH & Co. KG products in Australia. Link consists of a range of complex lower limb, hip and knee replacements, including oncology solutions. The Link products add to Allegra's well-developed range of products for distribution from international suppliers covering all specialties from foot and ankle to upper limb. The company is pleased to continue to build upon its extensive portfolio of patents. It has strong research relationships with universities, companies and surgeon inventors.